Janux Therapeutics, INC 8-K filings

Janux Therapeutics stockholders re-elected Class II directors and ratified the appointment of Ernst & Young LLP.

Janux Therapeutics reported Q1 2026 financial results, highlighting progress in its prostate cancer franchise with JANX007 and JANX014, and announced a $35 million milestone payment from a Bristol Myers Squibb collaboration.

Janux Therapeutics reclassified director Eric Dobmeier from Class III to Class II to balance board membership.

Janux Therapeutics announced its full year 2025 financial results and business highlights, showcasing continued clinical execution and a new collaboration with Bristol Myers Squibb.

Janux Therapeutics announced an exclusive worldwide license and collaboration agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors, potentially worth up to $800 million.

Janux Therapeutics announced its third quarter 2025 financial results, highlighting ongoing clinical trial enrollment for JANX007 and JANX008 and a strong cash position.

Janux Therapeutics announced the departure of Chief Strategy Officer Byron Robinson, Ph.D., effective September 18, 2025, under a 'termination without Cause' provision.

Janux Therapeutics announced its second quarter 2025 financial results, highlighting pipeline expansion, ongoing clinical trial enrollment, and a $10 million milestone payment from Merck.

Janux Therapeutics, Inc. announced the successful outcomes of its 2025 Annual Meeting of Stockholders, including the re-election of three Class I directors, ratification of Ernst & Young LLP as its independent auditor, and advisory approval of executive compensation.

Janux Therapeutics announces Q1 2025 financial results, highlighting the initiation of a Phase 1b expansion study for JANX007 and providing updates on its clinical programs.

Janux Therapeutics announces positive Phase 1 clinical trial data for JANX007 in mCRPC and reports a strong cash position of $1.03 billion as of December 31, 2024.

Janux Therapeutics has priced a public offering to raise $350 million through the sale of common stock and pre-funded warrants.

Janux Therapeutics reported promising interim clinical data for its JANX007 program in metastatic castration-resistant prostate cancer, leading to the selection of two dose regimens for Phase 1b expansion trials.

Janux Therapeutics announced its third quarter 2024 financial results, highlighting progress in clinical trials for its cancer immunotherapies and a strong cash position.

Janux Therapeutics announced its second quarter 2024 financial results, highlighted by a $7.5 million milestone payment from Merck and progress in clinical trials for its cancer therapies.

Janux Therapeutics announced the resignation of Jay Lichter, the appointment of Ron Barrett as Chairman, and the addition of Natasha Hernday and Eric Dobmeier to its Board of Directors.

Janux Therapeutics held its 2024 Annual Meeting of Stockholders, electing three Class III directors and ratifying Ernst & Young LLP as its independent accounting firm.

Janux Therapeutics announced its first quarter 2024 financial results, highlighting ongoing clinical trial enrollments and a strong cash position of $651.8 million.

Janux Therapeutics announced positive Phase 1 clinical trial results for its PSMA-TRACTr and EGFR-TRACTr programs, along with a strengthened balance sheet following a recent capital raise.

Janux Therapeutics has announced the pricing of a $296.5 million public offering of common stock and pre-funded warrants to advance its clinical pipeline and for general corporate purposes.

Janux Therapeutics has suspended its at-the-market equity offering, halting further sales of common stock under the existing agreement with BofA Securities.

Janux Therapeutics announces positive interim clinical data for its JANX007 and JANX008 cancer therapies, along with a strong cash position of approximately $338.2 million as of January 31, 2024.

Janux Therapeutics reports encouraging safety and efficacy data from ongoing trials of its PSMA-TRACTr and EGFR-TRACTr therapies in patients with advanced cancers.